In recent years numerous new vaccines have been developed, offering potential reductions in the morbidity and mortality caused by a range of diseases. This has led to increased interest in decision-making about the adoption of new vaccines into national immunization programmes. This paper aims to systematically review the literature on national decision-making around the adoption of new vaccines.
Introduction
In recent years numerous new vaccines have been developed, offering potential reductions in the morbidity and mortality caused by a range of diseases. However, these new vaccines differ from those included in the original expanded programme on immunization (EPI) that was established by the World Health Organization (WHO) in the 1970s (Kim-Farley 1992) . New vaccines tend to be considerably more expensive than existing vaccines and some target diseases which are relatively 'hidden' and therefore may lack demand from public and political perspectives (Clemens and Jodar 2005; Simpson et al. 2007) . These factors, combined with the reality that vaccines will continue to be developed, have helped to increase the attention paid to decision-making about the adoption of new vaccines into national immunization programmes (Clemens and Jodar 2005; Kimman et al. 2006; Andrus et al. 2007) . Despite this growing awareness of the importance of understanding decision-making in this field, it has been noted that there has been a 'neglect of issues of policy process and context' p. 1754 (Munira and Fritzen 2007) . This paper aims to review the literature on national decision-making around the adoption of new vaccines. It draws on a broad literature, including articles that describe examples of national decision-making and empirical studies which collected data or conducted analysis into decision-making and/or present frameworks to describe vaccine adoption decision-making.
Methods
A search strategy was developed in Medline and included both keyword and free text (title and abstract) terms relating to 'vaccines' or 'immunization' AND 'policy' or 'policy making' AND 'introduction' or 'adoption'. This strategy was then adapted for use in other databases (search strategies are available from the first author on request). In total, eight databases were searched in March 2010: Medline, Embase, Global Health, Eldis, Africa-wide NiPAD, HMIC (Health Management Information Consortium), Social Policy and Practice and the Global Health Library. The searches did not include any date or language limitations; however, searches were conducted in English only. Abstracts and full text articles (where necessary) were screened and data extracted in English, French, Portuguese and Norwegian (no potentially relevant articles were identified in other languages). References were then screened using the following exclusion criteria:
(1) Did not focus on human vaccination (e.g. focused on animal vaccination); (2) Did not focus on policy decision-making around vaccine adoption (i.e. considered decision-making at the clinical, individual level, or focused on implementation issues only, following a decision to adopt); (3) Did not explore examples of 'real' decision-making (e.g. focused on hypothetical vaccines)
AND
Did not present a framework for decision-making (i.e. a hypothetical study would only be included if it presented a decision-making framework) (4) Did not consider factors that directly affected decisions (e.g. assessed which macro-level factors, such as GDP, were associated with decisions to adopt, rather than focusing on the actual criteria considered within decision-making processes).
The titles and abstracts of the identified references were screened first and the full text of those not excluded using the above criteria (including those lacking sufficient information to exclude) were then retrieved and screened. Following screening, included articles were coded according to basic characteristics, such as the type of study and the country or vaccine focus. The frameworks were analysed using a grounded theory approach to search for themes and categories that emerged from the criteria included. A coding structure was developed using a sub-set of the included frameworks. Once this was finalised, it was applied to all the included frameworks. Using this data-driven, inductive approach, a comprehensive thematic framework was developed which aimed to encapsulate all the criteria of all the included frameworks. The studies describing examples of decisionmaking or collecting/analysing data on decision-making were then coded using this thematic framework. Since no quality appraisal tool exists (as far as the authors are aware) that can be applied to a range of study types, a tool for appraising qualitative research was adapted to assess the quality of the included empirical studies (Critical Appraisal Skills Programme 2006) . For the purpose of this study, question 2 ('is a qualitative methodology appropriate?') and question 6 ('has the relationship between researcher and participants been SYSTEMATIC REVIEW ON VACCINE DECISION-MAKING ii63 adequately considered?') were removed from the tool, in order to make it applicable to non-qualitative studies (Box 1). Studies were given scores for each of the remaining eight questions of either zero (if not stated), one (if partially addressed) or two (if completely satisfied the question), giving a maximum total score of 16.
Results
The searches identified a total of 3381 references, of which 728 were duplicates, leaving 2653 unique references (see Figure 1 ). Twenty-six additional references were identified through other sources (e.g. reference lists of included articles). Following screening, 85 references were included. Table 1 shows the number of studies excluded on each criterion. Of the included articles, 39 described examples of vaccine adoption decision-making, 26 presented frameworks of vaccine adoption decision-making and 21 collected or analysed empirical data on vaccine adoption decision-making. Nineteen of the included articles did not include a framework, an example or empirical data, and as such were considered to be theoretical essays (see Appendix 1 for details of the articles included).
Two of the included papers were systematic reviews. One synthesised five decision support tools for vaccination policy and another presented a systematic review of national immunization policy-making processes (Piso and Wild 2009; Bryson et al. 2010a) . The search strategy used in this latter review was narrower than that used in the current review, resulting in fewer articles identified for inclusion (Bryson et al. 2010a) . It focused mainly on national Immunization Technical Advisory Groups (ITAGs), which provide expert advice to government decision-makers.
Some studies and frameworks were presented in more than one paper. In these cases, each study or framework was included in the analysis only once, regardless of the number of publications relating to them. Combining linked papers in such a manner led to 76 studies/frameworks being included in the analysis.
Country focus
Similar numbers of papers focused on high-and low-/ middle-income countries, as defined by the World Bank; 27 and 27, respectively (World Bank 2010) . Thirteen papers were of a global nature, six focused on a mix of high-income countries and low-and middle-income countries, and three did not specify any particular country focus (Appendix 1).
Vaccine focus
Almost half of the articles (n ¼ 36) did not consider adoption decision-making for a specific vaccine. Of those that did, nine focused on vaccines for human papillomavirus (HPV) vaccine and eight on vaccines for Haemophilus influenzae type b (Hib). The decision to introduce rotavirus vaccine was explored in seven papers, six considered Hepatitis B vaccine and five looked at pneumococcus vaccine. The remainder considered vaccines targeting a range of diseases including rubella, meningococcal, yellow fever, varicella, tuberculosis and influenza (some papers considered more than one vaccine).
Findings: frameworks
Twenty-six papers presented frameworks for vaccine adoption decision-making. Five 'secondary' papers reported the same frameworks, leaving 21 unique frameworks included. The frameworks had a range of intended purposes. Four articles presented frameworks used by ITAGs (Ismail et al. 2010; Muangchana et al. 2010; Spicher 2010; Wijesinghe et al. 2010) ; another two presented frameworks that were used in studies of decision-making (Druce et al. 2006; Munira and Fritzen 2007) . The remainder presented frameworks that were either proposed for decision-making or used in hypothetical scenarios.
Because the frameworks were developed for a variety of purposes in a range of article types, it was difficult to assess the quality of the articles. Information was rarely included about how the frameworks had been developed, which particularly inhibited any quality assessment specific to the frameworks themselves.
An analysis of the frameworks identified nine broad categories of criteria (Table 2 ). For each of these categories, a variety of issues were considered by the different frameworks. These will now be discussed in greater detail, before being used to analyse the decision-making studies included in the review.
The importance of the health problem
Several factors were considered that related to the importance of the health problem, including both 'real' or objective measures and perceptions of its importance. However, only one-the burden of disease-was included in every framework. Some frameworks mentioned specific aspects of disease burden, such as the prevalence or incidence, severity (e.g. mortality, hospitalizations or disability) or the susceptibility of different sub-groups. Others included whether it was considered to be a political priority (or whether there was the political will to adopt the new vaccine), perceptions of the risk of the disease (e.g. among the public) and the social or economic costs of the disease. ii64 HEALTH POLICY AND PLANNING Downloaded from https://academic.oup.com/heapol/article-abstract/27/suppl_2/ii62/594578 by guest on 03 February 2019
Vaccine characteristics
The most common vaccine characteristic included in the frameworks was its efficacy or effectiveness, followed by its safety. These were included in 19 and 16 of the 21 frameworks, respectively. With regards to efficacy/effectiveness, some also mentioned consideration of the duration of immunity, the frequency of vaccine failure and the expected coverage rate needed for herd immunity to be achieved. Some frameworks also talked generally about the vaccine's characteristics or properties. Where examples were given, these included delivery issues (e.g. the route of administration and dosage), storage and preparation, or vaccine properties such as thermostability, the type of vaccine (e.g. live, attenuated etc.) or the preservatives used.
Immunization programme considerations
A range of issues relating to the implementation of a vaccination programme were included in the frameworks. Most (n ¼ 18) included some general criteria relating to the feasibility of delivering immunizations, such as the logistics required or legal issues. Issues relating to the supply of the vaccine were included in almost half the frameworks (n ¼ 10); some considered supply in general whilst others focused specifically on local vaccine production.
Acceptability
Just over half of the frameworks (n ¼ 12) considered aspects of the public acceptability of the new vaccine. Acceptability included the demand for, or acceptability of, immunization and could be influenced by perceptions of the disease risk or severity as well as the characteristics of the vaccine and vaccination programme. Compliance was also considered within acceptability in some frameworks, a factor which may affect immunization coverage rates. Two frameworks also mentioned the proposed vaccine's acceptability to health professionals.
Accessibility, equity and ethics
A third of the frameworks (n ¼ 7) included issues of accessibility, equity or other ethical issues. Where specified, equity tended to refer to the access to, uptake of, or coverage for either target groups or vulnerable groups of the population. Ethical considerations were explicitly mentioned in three frameworks, referring to the right to be protected (Feudtner and Marcuse 2001) , informed consent and protection of confidentiality (Piso and Wild 2009 ) and the broader evaluation of 'ethical, legal and social issues' p. 1610 (La Torre et al. 2008) .
Financial/economic issues
All but one of the frameworks included financial and/or economic criteria of one sort or another. The most common was the cost-effectiveness of the vaccine. The cost of the vaccine or the immunization programme, the funding sources available and its financial sustainability were also included in some frameworks. 
Impact of vaccination
Ten of the 21 frameworks included criteria about the impact that the new vaccine may have, if introduced. The impact on both health and non-health outcomes was considered. Health outcomes included reductions in disease prevalence or mortality, whilst non-health outcomes included economic benefits (e.g. reduced treatment costs at the individual or health care system levels) and social benefits (e.g. improved quality of life). Other considerations were the new vaccine's effect on other variants of the disease (i.e. serotypes not covered by the vaccine), or its effect on other vaccines.
Alternative interventions
Ten frameworks compared the proposed vaccine with alternative interventions, such as other vaccines or alternative prevention or treatment measures (e.g. water/sanitation improvements or antibiotics). Comparison was proposed in terms of cost, effectiveness and/or feasibility.
The decision-making process
The actual process of making vaccine adoption decisions was described in only four of the frameworks. Piso and Wild noted that, although included in their own framework, none of the five decision aids included in their review examined the decision-making process itself (Piso and Wild 2009 ). Druce et al. included the 'institutional and political context' in the 'dynamic decision making framework' for their study (Druce et al. 2006) . This included the roles of various actors, as well as the legislative and regulatory environment. Widdus noted that certain cues to action, including media coverage and advocacy, may influence the perceived threat of disease, which in turn may affect adoption decisions (Widdus 1999 ). Munira and The importance of the health problem Burden of disease (e.g. prevalence) 100% (21) 76% (31) Political priority 43% (9) 22% (9) Costs of disease 29% (6) 10% (4) Perceptions of importance (e.g. in terms of perceived severity or vulnerability)
29% (6) 7% (3) Other 19% (4) 5% (2) Vaccine characteristics Efficacy/effectiveness 90% (19) 68% (28) Vaccine safety 76% (16) 54% (22) Delivery issues (e.g. vaccine schedule) 38% (8) 10% (4) Other characteristics 38% (8) 5% (2) Programmatic considerations Feasibility 86% (18) 56% (23) Vaccine supply 48% (10) 22% (9) Acceptability Acceptability of vaccine 57% (12) 29% (12) Accessibility, equity and ethics Accessibility, equity and ethics 33% (7) 17% (7) Financial/economic issues Economic evaluation 86% (18) 83% (34) Incremental costs 43% (9) 24% (10) Funding sources 38% (8) 17% (7) Vaccine price 33% (7) 34% (14) Financial sustainability 19% (4) 29% (12) Other (including affordability) 24% (5) 49% (20) Impact of vaccination Impact on health outcomes 29% (6) 17% (7) Impact on non-health outcomes 29% (6) 12% (5) Effect of co-administration 24% (5) 5% (2) Risks of serotype replacement 10% (2) 12% (5) Other impact 14% (3) 15% (6) Consideration of alternative interventions Cost-effectiveness of alternatives 29% (6) 10% (4)
Effectiveness of alternatives 19% (4) 15% (6) Other considerations 33% (7) 7% (3)
Decision-making process Evidence sources/quality of evidence 24% (5) 59% (24) Actors involved 14% (3) 80% (33) Procedures 10% (2) 71% (29) Cues to action (e.g. disease outbreaks) 5% (1) 12% (5) a Studies may 'mention' criteria not only to report their influence on decision-making but also to note their lack of influence on decisions.
ii66 HEALTH POLICY AND PLANNING Fritzen included policy actors (and their interests), the decision-making process and context in their framework which may predict the uptake of new vaccines into policy (Munira and Fritzen 2007) . Another five frameworks included criteria relating to the use of evidence in decision-making. These mentioned a range of types of evidence, but commonly focused on evidence of the disease burden (e.g. from surveillance systems or specific studies), cost-effectiveness or effectiveness. Other lesscommonly mentioned evidence included whether there were existing recommendations or guidelines, whether research in general had been conducted and whether there was a need to conduct safety and immunogenicity studies in-country. LaTorre et al. looked at the potential role of health technology assessments (HTAs) which include a range of evidence types to support vaccine policy decision-making (La Torre et al. 2008) .
Summary: frameworks
The most common elements included in the frameworks were the burden of disease, financial/economic issues (particularly cost-effectiveness), the efficacy/effectiveness of the vaccine, the feasibility of vaccine delivery and the safety of the vaccine. Approximately half the frameworks included criteria relating to the acceptability of the vaccine, its potential impact, vaccine supply issues, or a comparison of the vaccine with alternative interventions. Few frameworks considered criteria relating to the decision-making process itself. The frameworks also lacked detail regarding how they had been developed. The categories identified from the analysis of the frameworks will now be applied to the studies of vaccine adoption decision-making.
Findings: examples of decision-making or empirical articles
Fifty articles described examples of vaccine adoption decision-making or collected/analysed data relating to decision-making. As mentioned above, some studies were reported in more than one article. In these cases, to avoid doublecounting, the analysis was conducted on the individual studies, rather than individual papers, such that 41 studies are described in this analysis. Thirty-five of these presented examples of decision-making or described the decision-making process and 16 were empirical studies (10 were both).
Of the empirical studies, 11 used qualitative methods, three were quantitative, one used mixed methods (qualitative and quantitative) and one was a systematic review. Table 3 presents the methods used.
The quality of the empirical studies was varied, with scores ranging from 4 to 14 (out of 16). The weakest of the eight criteria related to ethics; 11 of the 14 primary studies failed to mention ethical approval. Other 'weak' areas related to the justification and selection of the study design/methods used and the data analysis methods used, which were often not stated or described poorly. Eight studies scored 8 (50%) or more. To avoid limiting the review too much, it was decided that no studies would be excluded based on the quality appraisal. Therefore the remaining analysis is based on all of the empirical and 'example' studies.
Nearly half the studies focused on high-income countries (n ¼ 20) and 14 focused on low-and/or middle-income countries. Four included both high-and low-/middle-income countries and three were global (i.e. did not specify individual countries included, but focused at the international level).
The topics of the studies varied. Some presented general descriptions of the role of ITAGs in the decision-making process or specific examples of how or why an adoption decision was made (or why two countries' decisions differed). Others explored more specific elements of vaccine adoption decisionmaking, such as the role or importance of certain factors or types of actors, or stakeholders' perceptions of the factors important for decisions.
Importance of the health problem
Disease burden was noted in three-quarters of the articles (n ¼ 31), either highlighting its consideration in the decisionmaking process, or (among low-/middle-income countryfocused studies) the challenges and delays faced where such data were lacking.
Although the disease burden was frequently considered critical, a few studies reported that disease burden was not the most important criteria to consider. For example, the VENICE study of decision-making around HPV vaccine adoption in European countries found that the availability of epidemiological data did not appear to be associated with a decision to introduce the vaccine (King et al. 2008) . One empirical study and one example of decision-making reported that the public health impact or perceptions of the problem were more important than objective measures of disease burden (Brooks et al. 1999; Levy-Bruhl 2007) .
A quarter (10 studies) did not mention the burden of disease; most of these were focused on high-income countries (n ¼ 7). It is unclear whether this was because disease burden was not a key factor influencing decisions or whether the health problem was assumed to be known and accepted, such that stating this explicitly was not felt to be necessary.
A small number of studies considered other factors relating to the importance of the health problem, such as the political will to introduce a new vaccine, the costs of the disease or perceptions of risk of the disease.
Vaccine characteristics
Two-thirds of the studies (n ¼ 28) reported that efficacy or effectiveness were considered, or that these data were needed for decision-making. Approximately half noted that vaccine safety was considered. There was little difference in the proportion of high-income and low-/middle-income countryfocused studies mentioning efficacy or effectiveness; however, notably more high-income country studies discussed vaccine safety (14/20 high-income country studies versus 4/14 low-/ middle-income country studies). Only a small number explicitly considered other characteristics, such as delivery issues, although these may have been incorporated within considerations of the feasibility of introduction.
Immunization programme considerations
Although most frameworks included criteria relating to the feasibility of introducing the vaccine, just over half of the studies (n ¼ 23) reported the consideration of such programmatic issues. More of these focused on low-/middle-income countries than on high-income countries. Some studies (mainly of low-/ middle-income countries) considered vaccine supply issues.
Acceptability
Just over one-quarter of the studies (n ¼ 12) either noted the importance of public perceptions of the acceptability of the vaccine, or explicitly reported their consideration in decision-making. Most of these were focused on high-income countries; low-/middle-income country-focused studies rarely discussed acceptability issues. For example, Smith et al. describe how the Advisory Committee on Immunization Practices (ACIP) in the United States reviews many factors in making their decisions, including 'the acceptability of the immunizing agent' (Smith et al. 2009 ). Others noted that public demand, or social awareness of the issue, can either raise the issue on policy-makers' agendas, or make it easier for a positive adoption decision to be made. Negative, 'anti-vaccine' opinions and groups were also noted in some studies.
Accessibility, equity and ethics
Only a minority of studies (n ¼ 7) mentioned issues of equity, access or coverage (including one which noted their lack of consideration in vaccine adoption decisions) (Druce et al. 2006) .
Financial/economic issues
The majority of articles discussed financial/economic factors, although their reported influence on decision-making varied. In many articles, they were cited as key considerations in decision-making. High costs, low cost-effectiveness or a lack of funding available were given as reasons for not introducing new vaccines. Others noted that, although important to consider, financial/economic factors were not the dominant criteria. A small number of articles described cases where financial/economic information was not considered to be an important criterion for decision-making, or was explicitly excluded from decisions. These all focused on high-income countries ( Economic evaluations, such as cost-effectiveness analysis, were frequently considered critical for adoption decisions. A minority of high-income country studies noted that economic evaluations were not the most important factor in decisions, or described situations where decisions were made in spite of economic evidence to the contrary. Some low-/middle-income country-focused studies reported that there was a lack of economic evaluations, or financial data, available.
Other types of financial information were more likely to be discussed in studies focusing on low-/middle-income countries, such as financial sustainability, sources of funding, affordability and the vaccine price and vaccination programme costs. In contrast, high-income country-focused studies generally either did not mention costs or sources of funding, or explicitly noted their lack of importance for decision-making.
Impact of vaccination
A minority of studies mentioned issues around the predicted impact of vaccination, either in general or specifically affecting health or non-health outcomes. These were mainly high-income country-focused studies. The lack of reporting of predicted impact may in part be due to the non-explicit assessment of such issues, since it could be determined through consideration of disease burden and disease costs, the vaccine's effectiveness and issues that may affect the coverage of an immunization programme. Articles may have reported the use or influence of these separate factors, rather than the actual potential impact of vaccination.
A few high-income country studies considered the risk of serotype transmission, or the possibility of transmutation of the virus into a more virulent form.
Alternative interventions
A comparison of the vaccine with alternative interventions, such as screening (e.g. for cervical cancer), treatment, or alternative health interventions was discussed in one-fifth of the studies (n ¼ 9). These were mostly focused on high-income countries.
The decision-making process
Over three-quarters of the studies discussed the actors involved in the decision-making process (n ¼ 33). Donors and technical agencies (e.g. GAVI, WHO, UNICEF) were frequently cited as having a strong influence on decisions in the low-/middle-income country studies. The private sector was sometimes noted as being influential, as were the media, special interest groups (e.g. medical associations) and researchers. Some studies identified individual vaccine 'champions' who were particularly critical for certain decisions. The ITAG-focused papers generally described the Groups' membership; most had a range of expertise. Some were linked to and included government (e.g. Ministry of Health) staff, whilst others were more independent. Ministries of Finance were specifically noted in a few low-/middle-income country studies as not being included in vaccine adoption decision-making, or being brought in towards the end of the process.
A range of decision-making processes were described. For example, some ITAG recommendations were obligatory for the government to implement whilst others were only voluntary. Although nearly three-quarters of the studies looked at decision-making procedures, these were rarely explored in-depth. Just over half of the studies made reference to the evidence sources used in decision-making. Several noted that WHO guidelines and position papers were influential. Lack of data or information was a key challenge mentioned by a minority of mainly low-/middle-income country-focused studies. A few studies mentioned sharing information with, or looking at the experiences of, other countries, particularly in the same region. Whilst some reported that other countries' research may be considered, others noted a preference for local research and information. A small number explicitly mentioned consideration of the quality or origin of data, research or information.
Discussion
This analysis takes stock of what exists in terms of vaccine adoption decision-making frameworks. This is an important step if we are to understand how best to develop further both understandings of, and tools to support, vaccine adoption decision-making. A number of frameworks were identified in the review, and included a variety of criteria to inform vaccine adoption decision-making. These frameworks were synthesised into one overarching framework which contained nine broad categories which were then used to analyse the empirical studies in the review. However, it is not expected that these categories present a comprehensive framework that could be used in decision-making itself. Indeed, by incorporating all of the criteria included in a number of published frameworks, there may be too many elements for it to be user-friendly; some criteria may not be necessary. Further research is now required to test the comprehensive framework, in order to identify which elements are critical, how they may interact with each other and their relative importance in influencing decision-making. A refined framework can then be developed that is empirically grounded, to assist future research, as well as to help those hoping to influence vaccine adoption decision-making.
A diverse range of articles was identified, including those presenting decision-making frameworks, describing examples of decision-making, collecting stakeholder views or presenting theoretical perspectives. The heterogeneity of the study designs, methods and foci included in the review made synthesis a challenge. However, by analysing which criteria were considered in the studies, it is possible to identify what areas may be particularly important in decision-making, or where research has currently been focused.
Although some of the issues included in the frameworks were similar to those considered in the studies, there were also some notable differences. On the whole, the frameworks were more comprehensive than the studies, including a greater range of criteria. This may be because studies reported only factors that were most important, or highlighted particular criteria which were not considered in decisions. In contrast, the frameworks may have attempted to include all possible criteria which could influence decisions.
Only a few criteria were more frequently mentioned in the studies than included in the frameworks. These included the financial sustainability of introducing a new vaccine, other financial/economic issues, the effect of vaccination on virulence variants and other impacts of introduction. This suggests that these criteria may be more influential in decision-making than may have been recognised in the frameworks. The frameworks rarely included criteria relating to the actual process of decision-making, whilst the studies reported this more frequently (albeit without much detail). Gilson and Raphaely identified a similar weakness in the evidence base regarding a lack of detailed exploration of policy processes in their review of the health policy literature in low-and middle-income countries (Gilson and Raphaely 2008) .
The differences between the frameworks and the studies may be the result of differences that arise through the use of different methods, or varying foci of the papers. Differences due to methodological variety is a plausible explanation, particularly because some of the criteria noted as important in surveys of vaccine stakeholders differed from those reported in the rest of the studies identified. For example, although few of the included studies considered factors relating to the importance of the health problem (apart from the disease burden), one study found that 85% of national ITAGs surveyed reported considering the economic impact of the disease; 78% considered the disease priority relative to other vaccine-preventable diseases; and 59% reported considering public perceptions of risk (Bryson et al. 2010b) .
Overall, disease burden, the efficacy or effectiveness of the vaccine and financial/economic considerations were frequently reported to be key factors influencing vaccine adoption decision-making.
Several factors considered important in low-/middle-income countries frequently differed from those influencing decisions in high-income countries. Low-/middle-income country studies were less likely to mention vaccine safety issues and rarely discussed the acceptability of the vaccine, both of which were considered more frequently in the high-income country studies. This suggests that public perceptions were of greater import in high-income countries than in low-/middle-income countries. Programmatic issues, affordability and financial sustainability were more likely to be noted in low-/middle-income country studies than in high-income country studies. This is perhaps not surprising, given the health system weaknesses and financial constraints that are markedly more pronounced in low/middle-income countries than in high-income countries.
Conclusion
This review synthesises the literature on vaccine adoption decision-making, allowing the field to take stock of what is known and what weaknesses can be seen in the body of evidence as a whole. Without a clear evidence base detailing the factors considered in vaccine adoption decisions, it is not possible to assess the quality or utility of existing decisionmaking frameworks. This review has identified nine broad categories of criteria which may influence decisions. It seems clear that the relative importance of factors considered in decision-making varies according to the country context and the topic at hand. This categorization can be used in future studies not only to identify which criteria are particularly important and which are less relevant, but also how and why their influence may vary between settings and vaccines.
Poor descriptions of the methods of data collection and analysis used in the literature are a serious weakness in this
field. There is a need for more research exploring decisionmaking processes for vaccine adoption, particularly considering how decisions are made, rather than merely who was involved. This is particularly true for low-/middle-income countries. There have been few studies which have systematically explored the use and relative importance of different types of evidence in decision-making. This is a topic that has gathered substantial interest in the broader health research and policy fields in recent years; the vaccine field may also benefit from exploring the use of evidence in decision-making in greater detail.
The existing literature provides a good foundation for further research into national vaccine adoption decision-making. The current review, in pulling together what is already known and by identifying strengths, weaknesses and gaps in the existing evidence base, aims to encourage a more focused and rigorous approach to the topic in future. This could help to identify the most appropriate ways to enhance vaccine adoption decision-making, so as to improve decisions and, ultimately, health outcomes. In particular, this review has identified a lack of research exploring the process of decision-making, including issues of political pressures, the relative power of the stakeholders involved (or excluded from the process) and the extent to which the actual process reflected the official procedures in place. It is also clear that the quality of research in this area could be improved, through the use of more rigorous methods of data collection and analysis, as well as through the thorough reporting of both methods and findings. 
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